Rac1/pSTAT3 expression: a potential pharmacodynamic marker to optimize and individualize thiopurine therapy in IBD patients
Completed
- Conditions
- Inflammatory Bowel Disease (IBD)1001796910003816
- Registration Number
- NL-OMON50051
- Lead Sponsor
- Zuyderland Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 70
Inclusion Criteria
- Age between 18 - 70 years old
- Clinical, histological or endoscopic diagnosis of Crohn*s Disease, Ulcerative
colitis or IBDU (IBD-unclassified)
- Both hospitalized and ambulant patients are eligible
Exclusion Criteria
- current use of systemic corticosteroids
- age < 18 years and > 70 years.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary endpoint is the difference in Rac1 and pSTAT3 expression and<br /><br>activation in leucocytes of IBD patients on thiopurines and healthy volunteers. </p><br>
- Secondary Outcome Measures
Name Time Method <p>The secondary endpoints are the degree of Rac1 and pSTAT3 expression and<br /><br>activation in different types of white blood cells and the differences in Rac1<br /><br>and pSTAT3 expression and activation between all study groups. </p><br>